Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02163213

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D

Diarrhea-predominant Irritable Bowel Syndrome Clinical Trial

Official title:
An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Clinical Trial Summary

To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.

Clinical Trial Description

This is an open label study evaluating the impact of SBI 5.0 g twice daily on

1. nutritional status (plasma amino acid profile and kynurenine to tryptophan ratio),

2. intestinal permeability (in vivo) and

3. mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines status in patients with IBS-D.

Plasma, duodenal and stool samples will be collected. Fifteen eligible subjects will be enrolled to receive SBI for 8 weeks (SBI 5.0g BID for 8 weeks).

Intestinal permeability will be measured in vivo by two sugar urine excretion(s) after oral ingestion.

Biopsies from the distal second or third portion of the duodenum will be obtained endoscopically, to measure mRNA expression of tight junction proteins and markers of immune function, ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02163213
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase N/A
Start date June 2014
Completion date November 2, 2016
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04095988 - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) N/A
Completed NCT01736423 - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome Phase 3
Completed NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients
Completed NCT01414244 - Glutamine for the Treatment of Patients With Irritable Bowel Syndrome Phase 2
Not yet recruiting NCT06346847 - Study to Assess Effects of Pasteurized Akkermansia Muciniphila vs Placebo in Participants With Diarrhea-predominant IBS N/A
Completed NCT03977155 - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Terminated NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg Phase 3
Not yet recruiting NCT05687435 - Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2/Phase 3
Completed NCT01870895 - A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) Phase 3
Recruiting NCT05593367 - Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
Completed NCT02538692 - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Phase 2/Phase 3
Completed NCT03099785 - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Phase 2
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Completed NCT01350570 - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Phase 2/Phase 3